title: The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
abstract: Genetic heterogeneity in melanoma is well established. Given this, as well as the complexity of mechanisms involved in cancer in vivo, a more complete understanding of the development of resistance requires a closer look at the tumor ecosystem, including the microenvironment. Echoing this more comprehensive approach, a number of recent studies on BRAF-inhibitor resistance have brought our attention back to the tumor microenvironment, particularly through a focus on HGF-cMET signaling - a known means of stromal-parenchymal communication. Our review focuses on the results of these recent investigations, and through a review of relevant HGF-cMET past literature looks to provide a context by which to better understand the role of stromal-parenchymal signaling in BRAF resistance/melanoma progression.
authors: aDermatology Section, Dartmouth-Hitchcock Medical Center, Lebanon bDartmouth College, Hanover, NH cDepartment of Pathology and Laboratory Medicine, VA Medical Center, West Roxbury, MA, USA.
authors: Dan C
authors: DC
authors: Filitis
authors: Jake
authors: J
authors: Rauh
authors: Meera
authors: M
authors: Mahalingam
mesh_terms: D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D017228:Hepatocyte Growth Factor / Q000378:metabolism*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D059016:Tumor Microenvironment / Q000502:physiology*
chemical_list: C066855:HGF protein, human; D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf